Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to "tangible signs of a more constructive spending environment," with notable improvement in pharma and biotech end markets, and emphasized accelerating demand for tools that enable AI-driven science, particularly high-content screening instruments like the Opera Phenix OptIQ. He noted that these trends contributed to an elevated instrument backlog exiting the quarter, indicating strong underlying demand despite some delivery timing effects.
Is now the time to buy RVTY? Find out in our full research report (it’s free for active Edge members).
Revvity (RVTY) Q2 CY2026 Highlights:
- Revenue: $711.1 million vs analyst estimates of $707.2 million (4.5% year-on-year growth, 0.6% beat)
- Adjusted EPS: $1.41 vs analyst estimates of $1.22 (15.9% beat)
- The company slightly lifted its revenue guidance for the full year to $2.85 billion at the midpoint from $2.83 billion
- Management raised its full-year Adjusted EPS guidance to $5.35 at the midpoint, a 1.9% increase
- Operating Margin: 12.6%, in line with the same quarter last year
- Organic Revenue rose 3% year on year (beat)
- Market Capitalization: $12.94 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Revvity’s Q2 Earnings Call
- Dan Brennan (TD Cowen) asked about the size and impact of the Life Science instrument backlog and its implications for second-half growth. CEO Prahlad Singh and CFO Maxwell Krakowiak explained that the backlog is at its highest in three to four years, primarily due to timing of shipments and accelerating orders for complex instruments like OptIQ, positioning the company for stronger platform growth in the second half.
- Vijay Kumar (Evercore ISI) inquired about non-traditional AI customer orders and whether this shifts medium-term outlook for Life Science Solutions. Singh detailed that new demand is coming from AI-focused organizations and non-profits building drug discovery infrastructure, expanding Revvity’s addressable market.
- Michael Ryskin (Bank of America) questioned the slower-than-expected growth in reagents and the competitive environment. Krakowiak stated that reagent growth was low single digits in the first half, with expectations of a step-up in the fourth quarter as instrument placements convert to reagent usage.
- Puneet Souda (Leerink) sought clarity on the visibility of high-content analysis demand and confidence in software recovery. Singh emphasized that most instrument backlog is driven by high-content screening, while software growth should rebound due to contract renewals and new AI integrations.
- Jack Meehan (Operon Research) asked about the durability of newborn screening growth amid declining birth rates. Krakowiak responded that high single-digit reagent growth is sustained by geographic expansion and broader test menus, and further instrument placements support longer-term reagent sales.
Catalysts in Upcoming Quarters
In coming quarters, our team will be monitoring (1) the pace at which AI-driven demand translates into actual instrument and reagent revenue, (2) the timing and magnitude of Signals software recovery and customer adoption of new AI-enabled features, and (3) ongoing momentum in Diagnostics, particularly in reproductive health and newborn screening. Progress on manufacturing capacity expansion and the successful integration of recent acquisitions will also be important indicators of sustained operational execution.
Revvity currently trades at $120.91, up from $115.22 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
